Cost of Home Dialysis in France

Authors

DOI:

https://doi.org/10.25796/bdd.v5i3.67593

Keywords:

Home dialysis, peritoneal dialysis, Daily home hemodialysis, cost, Medico-economics

Abstract

Summary

Medico-economic evaluation is defined as economic evaluation applied to the health field. It is a comparative analysis of different diagnostic, therapeutic or preventive strategies, based on their costs and health outcomes. We have only one medico-economic study on the costs of dialysis in France, carried out by the Haute Autorité de Santé, which covered the year 2012 and consisted of cross-referencing 3 databases: the Registre Réseau Épidémiologique et Information en Néphrologie and the Système National d’Informations Inter-régimes de l’Assurance Maladie et de l’Hospitalisation. Analyses focused on prevalent patients, incident patients and key patient characteristics: age, presence of diabetes and care trajectories. The average monthly cost varied considerably according to the management modality, from 3774 euros/month in autonomous continuous ambulatory peritoneal dialysis (CAPD) to 7253 euros/month in center-based hemodialysis. The monthly cost of therapies according to the patient profile appears to be strongly affected by the diabetic status of the patients. This analysis shows the high cost of transport for patients on in-center hemodialysis (20% of total expenditures), and even higher for nursing care in assisted CAPD (37% of total expenditures). The total tariff decreases from 2014 to 2020 were -17.6% for center-based hemodialysis and -9.8% for the low medicalized dialysis unit (LMDU), while the total 2014–2021 tariff increases were +9.3% for CAPD and +9.1% for automated peritoneal dialysis (APD). Paradoxically, these price changes have increased the cost of assisted peritoneal dialysis, which is now almost at the same level of overall cost as in-center hemodialysis for the French health insurance system. The ongoing study of the Physidia Laboratory’s retrospective cohort on daily home hemodialysis (DHH) should allow us to know the current cost of each hemodialysis technique currently practiced in France, including DHH.

References

1. Améliorer la qualité de santé et maitriser les dépenses - Proposition de l’Assurance Maladie pour 2022 (Juillet 2021). Rapport au ministre chargé de la Sécurité sociale et au Parlement sur l’évolution des charges et des produits de l’Assurance Maladie au titre de 2021 (loi du 13 août 2004). Juillet 2021. https://assurance-maladie.ameli.fr/sites/default/files/rapport_charges_et_produits_-_propositions_de_lassurance_maladie_pour_2022_juillet_2021.pdf

2. Beresniak A, Duru G. Économie de la santé. Elsevier-Masson, Paris 08/2020 ; ISBN : 9782294769214

3. HAS - Agence de la Biomédecine. Rapport d’évaluation médico-économique. Évaluation médico-économique des stratégies de prise en charge de l’insuffisance rénale chronique terminale en France. Octobre 2014. https://www.has-sante.fr/jcms/c_1775180/fr/evaluation-medico-economique-des-strategies-de-prise-en-charge-de-l-insuffisance-renale-chronique-terminale-en-france.
Argumentaire : https://www.has-sante.fr/upload/docs/application/pdf/2014-11/argumentaire_irct_vf_2014-11-06_19-21-13_876.pdf
Annexe : https://www.has-sante.fr/upload/docs/application/pdf/2014-11/annexes_irct_vf.pdf. Fiche de synthèse : https://www.has-sante.fr/upload/docs/application/pdf/2014-11/fiche_de_sytnhese_vf.pdf.
Synthèse et conclusions : https://www.has-sante.fr/upload/docs/application/pdf/2014-11/synthese_irct_vf.pdf

4. Zambrowski JJ. Coût de la dialyse. Néphrologie & Thérapeutique. 2016;12S: S95-S97. doi : 10.1016/j.nephro.2016.02.002

5. Bechu T. Note interne de la Fédération des Cliniques et Hôpitaux Privés branche Médecine, Chirurgie et Obstétrique (FHP MCO) sur l’évolution des financements de la dialyse durant les années 2014-2021

6. Thomas M, Directeur Médical Physidia. Communication personnelle 2021

7. Walker RC, Howard K, Morton RL. Home hemodialysis: a comprehensive review of patient-centered and economic considerations. Clinicoecon Outcomes Res. 2017;9:149-161. doi : 10.2147/CEOR.S69340

8. Rostoker G, Issad B, Fessi H, Massy ZA. Why and how should we promote home dialysis for patients with end-stage kidney disease during and after the coronavirus 2019 disease pandemic? A French perspective. J Nephrol. 2021;34(4):985-989. doi: 10.1007/s40620-021-01061-7.

9. Baerman EA, Kaplan J, Shen JI, Winkelmayer WC, Erickson KF. Cost Barriers to more widespread use of peritoneal dialysis in the United States. J Am Soc Nephrol 2022;33(6):1063-1072, doi: 10.1681/ASN.2021060854

10. Rostoker G, Issad B. Financial barriers to optimal use of peritoneal dialysis in France and Europe as in United States of America. J Am Soc Nephrol, under Submission

Published

2022-09-06

How to Cite

1.
Rostoker G. Cost of Home Dialysis in France. Bull Dial Domic [Internet]. 2022 Sep. 6 [cited 2024 Apr. 24];5(3):213-22. Available from: https://www.bdd.rdplf.org/index.php/bdd/article/view/67593

Issue

Section

Home dialysis day (DIADOM) of Universitary Seminars of Nephrology , Paris 2022